Nalt-versus Peyer's-patch-mediated mucosal immunity

Nature Reviews Immunology

Volumn 4, Issue 9, 2004, Pages 699-710

  Kiyono, Hiroshi ^a   Fukuyama, Satoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADDRESSIN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR5; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; I KAPPA B KINASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; LYMPHOTOXIN; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PNEUMOCOCCUS VACCINE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; VACCINE; VASCULAR CELL ADHESION MOLECULE 1;

B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EMBRYO DEVELOPMENT; HUMAN; IMMUNIZATION; IMMUNOGLOBULIN GENE; LYMPHOID TISSUE; MUCOSAL IMMUNITY; NASOPHARYNX; NASOPHARYNX ASSOCIATED LYMPHOID TISSUE; NONHUMAN; NOSE MUCOSA; ORGANOGENESIS; PEYER PATCH; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; WALDEYER RING;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNITY, MUCOSAL; LYMPH NODES; NASOPHARYNX; PEYER'S PATCHES;

EID: 4544258068     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1439     Document Type: Review

References (102)

1. Mestecky, J., Blumberg, R., Kiyono, H. & McGhee, J. R. in Fundamental Immunology 5th edn Ch. 31 (ed. Paul, W. E.) 965-1020 (Academic, San Diego, 2003).
2. Yuki, Y. & Kiyono, H. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13, 293-310 (2003).
3. Csencsits, K. L., Jutila, M. A. & Pascual, D. W. Nasal-associated lymphoid tissue: phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site. J. Immunol. 163, 1382-1389 (1999).
4. Adachi, S., Yoshida, H., Kataoka, H. & Nishikawa, S. Three distinctive steps in Peyers patch formation of murine embryo. Int. Immunol. 9, 507-514 (1997).
5. + inducer cells are involved in the postnatal initiation of NALT genesis. In addition, together with reference 31, it described that NALT organogenesis is independent of IL-7R- and LT-βR-mediated signalling.
6. Hashi, H. et al. Compartmentalization of Peyer's patch anlagen before lymphocyte entry. J. Immunol. 166, 3702-3709 (2001).
7. Hameleers, D. M., van der Ende, M., Biewenga, J. & Sminia, T. An immunohistochemical study on the postnatal development of rat nasal-associated lymphoid tissue (NALT). Cell Tissue Res. 256, 431-438 (1989).
8. De Togni, R et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 703-707 (1994).
9. Futterer, A., Mink, K., Luz, A., Kosco-Vilbois, M. H. & Pfeffer, K. The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9, 59-70 (1998).
10. Rennert, P. D., Browning. J. L., Mebius, R., Mackay, F. & Hochman, P. S. Surface lymphotoxin α/β complex is required for the development of peripheral lymphoid organs. J. Exp. Med. 184, 1999-2006 (1996).
11. Koni, P. A. et al. Distinct roles in lymphoid organogenesis for lymphotoxins α and β revealed in lymphotoxin β-defident mice. Immunity 6, 491-500 (1997).
12. - cells in the embryonc intestine induces the organizing center of Peyer's patches. Int. Immunol. 11, 643-655 (1999).
13. Yamamoto, M. et al. Alternate mucosal immune system: organized Peyer's patches are not required for IgA responses in the gastrointestinal tract. J. Immunol. 164, 5184-5191 (2000).
14. Mauri, D. N. et al. LIGHT a new member of the TNF superfamity, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 8, 21-30 (1998).
15. Scheu, S. et al. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin β in mesenteric lymph node genesis. J. Exp. Med. 195, 1613-1624 (2002).
16. Fujihashi, K. et al. Interleukin 2 (IL-2) and interleukin 7 (IL-7) reciprocally induce IL-7 and IL-2 receptors on γδ T-cell receptor-positive intraepithelial lymphocytes. Proc. Natl Acad. Sci. USA 93, 3613-3618 (1996).
17. Watanabe, M. et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J. Clin. Invest. 95, 2945-2953 (1995).
18. Fujihashi, K., McGhee, J. R., Yamamoto, M., Peschon, J. J. & Kiyono, H. An interleukin-7 intemet for intestinal intraepithelial T cell development: knockout of ligand or receptor reveal deferences in the immunodeficient state. Eur. J. Immunol. 27, 2133-2138 (1997).
19. Adachi, S. et al. Essential role of IL-7 receptor α in the formation of Peyer's patch anlage. Int. Immunol. 10, 1-6 (1998).
20. + cells as a novel cell subset that contributes to the development of lymphoid organs.
21. + cells induce the organogenesis of Peyer's patches in a CXCR5-dependent manner.
22. Honda, K. et al. Molecular basis for hematopoietic/mesenchymal interaction during initiation of Peyer's patch organogenesis. J. Exp. Med. 193, 621-630 (2001).
23. Peschon, J. J. et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180, 1955-1960 (1994).
24. Forster, R. et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87, 1037-1047 (1996).
25. Shinkura, R. et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding NF-κB-inducing kinase. Nature Genet. 22, 74-77 (1999).
26. Nakano, H. et al. TRAF5, an activator of NF-κB and putative signal transducer for the lymphotoxin-β receptor. J. Biol. Chem. 271, 14661-14664 (1996).
27. Miyawaki, S. et al. A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur. J. Immunol. 24, 429-434 (1994).
28. Yin, L et al. Defective lymphotoxin-β receptor-induced NFκB transcriptional activity in NIK-deficient mice. Science 291, 2162-2165 (2001).
29. Sun, Z. et al. Requirement for RORγ in thymocyte survival and lymphoid organ development. Science 288, 2369-2373 (2000).
30. Yokota, Y et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397, 702-706 (1999).
31. Harmsen, A. et al. Organogenesis of nasal-associated lymphoid tissue (NALT) occurs independently of lymphotoxin-α (LTα) and retinoic acid receptor-related orphan receptor-γ, but the organization of NALT is LTα dependent. J. Immunol. 168, 986-990 (2002).
32. Eberl, G. et al. An essential function for the nuclear receptor RORγ in the generation of fetal lymphoid tissue inducer cells. Nature Immunol. 5, 64-73 (2004).
33. Kurebayashi, S. et al. Retinoid-related orphan receptor γ (RORγ) is essential for lymphoid organogenesis and control apoptosis during thymopoiesis. Proc. Natl Acad. Sci. USA 97, 10132-10137 (2000).
34. Kuper, C. F. et al. Lymphoid and non-lymphoid cells in nasal-associated lymphoid tissue (NALT) in the rat. An immuno- and enzyme-histochemical study. Cell Tissue Res. 259, 371-377 (1990).
35. Kuper, C. F. et al. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13, 219-224 (1992).
36. Debertin, A. S. et al. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin. Exp. Immunol. 134, 503-507 (2003).
37. Spit, B. J. et al. Nose-associated lymphoid tissue (NALT) in the rat. Ultramicroscopy 21, 201-204 (1987). This study of rats was the first to characterize NALT, which consists of T- and B-cell areas and M cells.
38. Porgador, A., Staats, H. F., Itoh, Y. & Kelsall, B. L. Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. Infect. Immun. 68, 5876-5881 (1998).
39. Zuercher, A. Z., Coffin, S. E., Thumheer, M. C., Fundora, P. & Cebra, J. J. Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J. Immunol, 168, 1796-1803 (2002).
40. Prakken, B. J., et al. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc. Natl Acad. Sci. USA. 94, 3284-3289 (1997).
41. H2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J. Immunol. 162, 3559-3565 (1999).
42. H2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur. J. Immunol. 28, 3346-3353 (1998).
43. H2-deficient conditions. J. Immunol. 167, 5862-5867 (2001).
44. H2 help for virus-specific immune responses in reproductive tissues. J. Immunol. 161, 5952-5958 (1998).
45. H2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J. Infect. Dis. 180, 122-132 (1999).
46. Spalding, D. M. & Griffin, J. A. Different pathways of differentiation of pre-B cell lines are induced by dendritic cells and T cells from different lymphoid tissues. Cell 44, 507-515 (1986).
47. Iwasaki, A. & Kelsall, B. L. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 190, 229-239 (1999).
48. Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563 (2000).
49. Coffman, R. L., Lebman, D. A. & Shrader, B. Transforming growth factor β specifically enhances IgA production by ipopolysaccharide- stimulated murine B lymphocytes, J. Exp. Med. 170, 1039-1044 (1989).
50. Sonoda, E. et al. Transforming growth factor β induces IgA production and acts additively with interleukin 5 for IgA production. J. Exp. Med. 170, 1415-1420 (1989).
51. + B cells regardless of the method of B cell activation. J. Immunol. 148, 3830-3836 (1992).
52. Bowman, E. P. et al. The intestinal chemokine thymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells. J. Exp. Med. 195, 269-275 (2002).
53. Youngman, K. R. et al. Correlation of tissue distribution, developmental phenotype, and intestinal homing receptor expression of antigen-specific B cells during the murine anti-rotavirus immune response. J. Immunol. 168, 2173-2181 (2002).
54. Murray, P. D., McKenzie, D. T., Swain, S. L. & Kagnoff, M. F. Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression. J. Immunol. 139, 2669-2674 (1987).
55. Coffman, R. L., Shrader, B., Carty, J., Mosmann, T. R. & Bond, M. W. A mouse T cell product that preferentially enhances IgA production. I. Biologic characterization. J. Immunol. 139, 3685-3690 (1987).
56. Beagley, K. W. et al. Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J. Immunol. 141, 2035-2042 (1988).
57. Beagley, K. W. et al. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J. Exp. Med. 169, 2133-2148 (1989).
58. Defrance, T. et al. Interleukin 10 and transforming growth factor β cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J. Exp. Med. 175, 671-682 (1992).
59. Fagarasan, S., Kinoshita, K., Muramatsu, M., Ikuta, K. & Honjo, T. In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. Nature 413, 639-643 (2001).
60. Kang, H.-S., et al. Signaling via LTβR on the lamina propria stromal cells of the gut is required for IgA production. Nature Immunol. 3, 576-582 (2002).
61. Davis, I. A., Knight, K. A. & Rouse, B. T. The spleen and organized lymph nodes are not essential for the development of gut-induced mucosal immune responses in lymphotoxin-α deficient mice. Clin. Immunol. Immunopathol. 89, 150-159 (1998).
62. Hamada, H. et al. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J. Immunol. 168, 57-64 (2002).
63. Brandtzaeg, P., Baekkevold, E. S. & Morton, H. C. From B to A the mucosal way. Nature Immunol. 2, 1093-1094 (2001).
64. Fagarasan, S. & Honjo, T. Intestinal IgA synthesis: regulation of front-line body defences. Nature Rev. Immunol. 3, 63-72 (2003).
65. Kroese, F. G., de Waard, R. & Bos, N. A. B-1 cells and their reactivity with the murine intestinal microflora. Semin. Immunol 8, 11-18 (1996).
66. Hiroi, T. et al. Deficiency of IL-5 receptor α-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues. J. Immunol. 162, 821-828 (1999).
67. Jang, M. H. et al. Intestinal villous M cell: an antigen entry site in the mucosal epithelium. Proc. Natl Acad Sci. USA 101, 6110-6115 (2004).
68. Shikina, T. et al. IgA class switch occurs in the organized nasopharynx- and gut-assodated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J. Immunol. 172, 6259-6264 (2004).
69. Iwasato, T., Shimizu, A., Honjo, T. & Yamagishi, H. Circular DNA is excised by immunoglobulin class switch recombination. Cell 62, 143-149 (1990).
70. + memory B cells that have high affinity for antigen.
71. Lazarus, N. H. et al. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J. Immunol. 170, 3799-3805 (2003).
72. Kunkel, E. J. et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J. Clin. Invest. 111, 1001-1010 (2003).
73. Kunkel, E. J. & Butcher, E. C. Plasma-cell homing. Nature Rev. Immunol. 3, 822-829 (2003).
74. Yonemitsu, Y. et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nature Biotechnol. 18, 970-973 (2000).
75. Kunisawa, J. et al. Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system. J. Immunol. 167, 1406-1412 (2001).
76. Sakaue, G. et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. 170, 495-502 (2003).
77. Park, H. S., Francis, K. P., Yu, J. & Cleary, P. P. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A Streptococcus. J. Immunol. 171, 2532-2537 (2003).
78. Wolf, J. L. et al. Intestinal M cells: a pathway for entry of reovirus into the host. Science 212, 471-472 (1981).
79. Lee, P. W., Hayes, E. C. & Joklik, W. K. Protein σ 1 is the reovirus cell attachment protein. Virology 108, 156-163 (1981).
80. Wu, Y. et al. M cell-targeted DNA vaccination. Proc. Natl Acad. Sci. USA 98, 9318-9323 (2001). This paper showed the efficacy of NALT M-cell-targeted DNA immunization for the induction of antigen-specific immune responses.
81. Wang, X., Hone, D. M., Haddad, A., Shata, M. T. & Pascual, D. W. M cell DNA vaccination for CTL immunity to HIV. J. Immunol. 171, 4717-4725 (2003).
82. Honda, M. et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl Acad. Sci. USA 92, 10693-10697 (1995).
83. Aldovini, A. & Young, R. A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351, 479-482 (1991).
84. Yamamoto, M., McGhee, J. R., Hagiwara, Y., Otake, S. & Kiyono, H. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand. J. Immunol. 53, 211-217 (2001).
85. de Haan, L. et al. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect. Immun. 64, 5413-5416 (1996).
86. Douce, G. et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl Acad. Sci. USA 92, 1644-1648 (1995). This study showed that a mutant form of enterotoxin that lacks toxicity is useful as a mucosal adjuvant for nasal immunization.
87. Fontana, M. R. et al. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect Immun. 63, 2356-2360 (1995).
88. Freytag, L. C. & Clements, J. D. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236, 216-236 (1999).
89. Yamamoto, S. et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185, 1203-1210 (1997).
90. Yamamoto, M. et al. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161, 4115-4121 (1998).
91. H2-type responses for enhanced mucosal immunity. Proc. Natl Acad. Sci. USA 94, 5267-5272 (1997).
92. Hagiwara, Y. et al. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine. Vaccine 17, 2918-2926 (1999).
93. Kweon, M. N. et al. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J. Infect. Dis. 186, 1261-1269 (2002).
94. Nakamura, K. & Okuno, Y. Vaccination with live attenuated influenza virus at the Osaka university hospital in 1960. Virus 11, 349-354 (1961).
95. Okuno, Y. & Nakamura, K. Prophylactic effectiveness of live influenza vaccine in 1965. Biken J. 9, 89-95 (1966).
96. Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 360, 896-903 (2004).
97. Bourguignon, P. et al. in Molecular Approaches to Vaccine Design 23 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1999).
98. Gluck, U., Gebbers, J. O. & Gluck, R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labiie toxin in adult volunteers. J. Virol. 73, 7780-7786 (1999).
99. King, J. C. et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect Dis. 177, 1394-1397 (1998).
100. Harper, S. A., Fukuda, K., Cox, N. J. & Bridges, C. B. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm. Rep. 52 (Suppl RR-13), 1-8 (2003).
101. Maassab, H. F. Adaptation and growth characteristics of influenza virus at 25°C. Nature 213, 612-614 (1967).
102. Bukreyev, A. et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363, 2122-2127 (2004).